SG11202112407PA - Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators - Google Patents

Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators

Info

Publication number
SG11202112407PA
SG11202112407PA SG11202112407PA SG11202112407PA SG11202112407PA SG 11202112407P A SG11202112407P A SG 11202112407PA SG 11202112407P A SG11202112407P A SG 11202112407PA SG 11202112407P A SG11202112407P A SG 11202112407PA SG 11202112407P A SG11202112407P A SG 11202112407PA
Authority
SG
Singapore
Prior art keywords
receptor modulators
substituted pyrazolo
pyridine amides
glun2b receptor
glun2b
Prior art date
Application number
SG11202112407PA
Other languages
English (en)
Inventor
Afton Hiscox
Akinola Soyode-Johnson
Brice Stenne
Christa Chrovian
Christine Gelin
Andrew Samant
Michael A Letavic
Curt Dvorak
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP200101623A external-priority patent/AR119125A1/es
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11202112407PA publication Critical patent/SG11202112407PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202112407PA 2019-06-14 2020-06-12 Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators SG11202112407PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962861656P 2019-06-14 2019-06-14
PK35020 2020-06-03
ARP200101623A AR119125A1 (es) 2019-06-14 2020-06-09 Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
PCT/EP2020/066392 WO2020249792A1 (en) 2019-06-14 2020-06-12 Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators

Publications (1)

Publication Number Publication Date
SG11202112407PA true SG11202112407PA (en) 2021-12-30

Family

ID=73781829

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112407PA SG11202112407PA (en) 2019-06-14 2020-06-12 Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators

Country Status (21)

Country Link
US (2) US11618750B2 (ko)
EP (1) EP3983075A1 (ko)
JP (1) JP2022536522A (ko)
KR (1) KR20220024511A (ko)
CN (1) CN113993868A (ko)
AU (1) AU2020290016A1 (ko)
BR (1) BR112021024856A2 (ko)
CA (1) CA3142996A1 (ko)
CL (1) CL2021003277A1 (ko)
CO (1) CO2021016003A2 (ko)
CR (1) CR20210580A (ko)
DO (1) DOP2021000251A (ko)
EC (1) ECSP21090478A (ko)
IL (1) IL288859A (ko)
JO (1) JOP20210328A1 (ko)
MA (1) MA56196A (ko)
MX (1) MX2021015506A (ko)
PE (1) PE20220386A1 (ko)
SG (1) SG11202112407PA (ko)
TW (1) TW202112774A (ko)
WO (1) WO2020249792A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
JOP20210328A1 (ar) 2019-06-14 2023-01-30 Janssen Pharmaceutica Nv مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات "glun2b"
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
AU2020293584A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GluN2B receptor modulators
JP2022536773A (ja) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
WO2020249796A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
JP3192662B2 (ja) 1996-07-31 2001-07-30 日研化学株式会社 ６―フェニルテトラヒドロ―１，３―オキサジン―２―オン誘導体及びそれを含む医薬組成物
JP2004501901A (ja) 2000-06-26 2004-01-22 メルク　エンド　カムパニー　インコーポレーテッド イミノピリミジン系ｎｍｄａｎｒ２ｂ受容体拮抗薬
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
US7534800B2 (en) 2002-03-28 2009-05-19 Eisai R & D Development Co., Ltd. 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
EA200601266A1 (ru) 2004-02-18 2007-02-27 Астразенека Аб Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
US7622486B2 (en) 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
KR101418024B1 (ko) * 2005-06-22 2014-07-16 케모센트릭스, 인크. 아자인다졸 화합물 및 사용방법
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
TWI443090B (zh) 2007-05-25 2014-07-01 Abbvie Deutschland 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
EP2194045A4 (en) 2007-08-30 2011-09-21 Takeda Pharmaceutical SUBSTITUTED PYRAZOLE DERIVATIVE
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
MX2010009649A (es) 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
WO2009157196A1 (ja) 2008-06-25 2009-12-30 武田薬品工業株式会社 アミド化合物
NZ590688A (en) 2008-08-05 2012-09-28 Daiichi Sankyo Co Ltd imidazo[4,5-b]pyridin-2-one derivatives
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
US8969342B2 (en) 2009-03-20 2015-03-03 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
US8765784B2 (en) 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
EP2582666B1 (en) * 2010-06-16 2014-08-13 Purdue Pharma L.P. Aryl substituted indoles and their use as blockers of sodium channels
JP5990106B2 (ja) * 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
JP2012188363A (ja) 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd アザベンゾイミダゾロン誘導体
PL2570415T3 (pl) 2011-09-19 2016-01-29 Sanofi Sa N-[4-(1H-pirazolo[3,4-b]pirazyn-6-ylo)-fenylo]-sulfonamidy i ich zastosowanie jako farmaceutyki
WO2013060029A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Allosteric modulators of metabotropic glutamate receptors
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
WO2014160017A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
NZ630875A (en) 2013-03-15 2017-12-22 Plexxikon Inc Heterocyclic compounds and uses thereof
ES2806135T3 (es) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd Nuevos inhibidores de bromodominios bicíclicos
LT3049417T (lt) 2013-07-31 2019-02-11 Merck Patent Gmbh Piridinai, pirimidnai ir pirazinai kaip btk inhibitoriai ir jų panaudojimas
WO2016025917A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
US10155727B2 (en) 2014-08-15 2018-12-18 Janssen Pharmaceuticals, Inc. Pyrazoles
WO2016081649A1 (en) 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
MA41803A (fr) * 2015-03-24 2018-01-30 Almirall Sa Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
KR20180026760A (ko) 2015-07-09 2018-03-13 얀센 파마슈티카 엔.브이. 치환된 4-아자인돌 및 glun2b 수용체 조절제로서의 이의 용도
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
CA3066423A1 (en) 2017-06-14 2018-12-20 Trevena, Inc. Compounds for modulating s1p1 activity and methods of using the same
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
CN110294756A (zh) 2019-06-04 2019-10-01 广州市原子高科同位素医药有限公司 GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
AU2020293584A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GluN2B receptor modulators
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
JOP20210328A1 (ar) 2019-06-14 2023-01-30 Janssen Pharmaceutica Nv مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات "glun2b"
JP2022536773A (ja) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
WO2020249796A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators

Also Published As

Publication number Publication date
TW202112774A (zh) 2021-04-01
ECSP21090478A (es) 2022-01-31
WO2020249792A1 (en) 2020-12-17
JOP20210328A1 (ar) 2023-01-30
CL2021003277A1 (es) 2022-08-19
JP2022536522A (ja) 2022-08-17
CO2021016003A2 (es) 2021-12-10
MA56196A (fr) 2022-04-20
IL288859A (en) 2022-02-01
KR20220024511A (ko) 2022-03-03
US20210017168A1 (en) 2021-01-21
CA3142996A1 (en) 2020-12-17
PE20220386A1 (es) 2022-03-18
BR112021024856A2 (pt) 2022-01-18
EP3983075A1 (en) 2022-04-20
US11618750B2 (en) 2023-04-04
US20230151006A1 (en) 2023-05-18
AU2020290016A1 (en) 2022-01-06
MX2021015506A (es) 2022-02-10
DOP2021000251A (es) 2022-04-18
CN113993868A (zh) 2022-01-28
CR20210580A (es) 2022-01-31

Similar Documents

Publication Publication Date Title
IL288859A (en) Converted pyrazolo-pyridine amides and their use as glun2b receptor modulators
IL282257A (en) Androgen receptor modulators and methods of using them
IL288858A (en) Transmuted heteroaromatic pyrazolopyridines and their use as glun2b receptor modulators
IL276295A (en) Modulators of chemokine receptors and their uses
IL276332A (en) Spiro-lactam NMDA receptor modulators and their use
IL276330A (en) Spiro-lactam NMDA receptor modulators and their use
HK1255160A1 (zh) 取代的4-氮雜吲哚以及它們作為glun2b受體調節劑的用途
IL291029A (en) New modulators of 5-hydroxytryptamine receptor 7 and a method of using them
EP3600290A4 (en) NEW SIGMA 2 RECEIVER MODULATORS AND THEIR OPERATING PROCEDURE
ZA202105847B (en) Mtroc modulators and uses thereof
IL273954A (en) Converted imidazopyridine amides and their use
EP3600289A4 (en) 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THE USE OF THESE AS THERAPEUTIC AGENTS
DK3830092T3 (en) Heteroaromatic nmda receptor modulators and uses thereof
HK1245259A1 (zh) 作為nmda受體調節劑的吡啶並嘧啶酮類及它們的用途
EP3962510C0 (en) NOVEL SELECTIVE ACKR3 MODULATORS AND THEIR USES
GB201906914D0 (en) Substituted naphtahlene diimdes and their use